Test-positive rate at CT colonography is increased by rectal bleeding and/or unexplained weight loss, unlike other common gastrointestinal symptoms  by Hock, D. et al.
AP
t
M
y
i
C
c
R
t
p
0
o
1
C
t
©
l
K
1
d
c
P
t
c
[
i
p
h
2
bAvailable  online  at  www.sciencedirect.com
ScienceDirect
European Journal of Radiology Open 2 (2015) 32–38
Test-positive rate at CT colonography is increased by rectal bleeding and/or
unexplained weight loss, unlike other common gastrointestinal symptoms
D. Hock a,∗, R. Materne a, R. Ouhadi a, I. Mancini a, S.A. Aouachria a, A. Nchimi b
a Department of Medical Imaging, Centre Hospitalier Chrétien (CHC), Rue de Hesbaye, 75, B-4000 Liège, Belgium
b Department of Thoracic and Cardiovascular Imaging, CHU de Liège, Domaine Universitaire du Sart Tilman, Bâtiment B 35, B-4000 Liège, Belgium
Received 19 December 2014; accepted 23 December 2014
Available online 8 January 2015
bstract
urpose:  We evaluated the rate of significant colonic and extra-colonic abnormalities at computed tomography colonography (CTC), according
o symptoms and age.
aterials  and  methods:  We retrospectively evaluated 7361 consecutive average-risk subjects (3073 males, average age: 60.3 ±  13.9; range 18–96
ears) for colorectal cancer (CRC) who underwent CTC. They were divided into three groups according to clinical symptoms: 1343 asymptomatic
ndividuals (group A), 899 patients with at least one “alarm” symptom for CRC, including rectal bleeding and unexplained weight loss (group
), and 5119 subjects with other gastrointestinal symptoms (group B). Diagnostic and test-positive rates of CTC were established using optical
olonoscopy (OC) and/or surgery as reference standard. In addition, clinically significant extra-colonic findings were noted.
esults:  903 out of 7361 (12%, 95% confidence interval (CI) 0.11–0.13) subjects had at least one clinically significant colonic finding at CTC. CTC
rue positive fraction and false positive fraction were respectively 637/642 (99.2%, 95%CI 0.98–0.99) and 55/692 (7.95%, 95%CI 0.05–0.09). The
ooled test-positive rate in group C (138/689, 20.0%, 95%CI 0.17–0.23) was significantly higher than in both groups A (79/1343, 5.9%, 95%CI
.04–0.07) and B (420/5329, 7.5%, 95%CI 0.07–0.08) (p  < 0.001). Aging and male gender were associated to a higher test positive rate. The rate
f clinically significant extra-colonic findings was significantly higher in group C (44/689, 6.4%, 95%CI 0.04–0.08) versus groups A (26/1343,
.9%, 95%CI 0.01–0.02) and B (64/5329, 1.2%, 95%CI 0.01–0.02) (p  < 0.001).
onclusion:  Both test-positive and significant extra-colonic finding rates at CTC are significantly increased in the presence of “alarm” gastroin-
estinal symptoms especially in older patients.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
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.  Introduction
Colorectal cancer (CRC) is the second cause of cancer-related
eath [1] and generally results from the transformation of clini-
ally silent adenomas [2] that are sought by screening tests [3].
ersistence or sudden occurrence of various abdominal symp-
oms is often considered an indication to search or rule out
olonic abnormalities, including CRC or precancerous polyps
4]. Literature suggests that the use of optical colonoscopy (OC)
s warranted only for subjects with rectal bleeding and unex-
lained weight loss [5], whereas the other symptoms’ specificity
∗ Corresponding author. Tel.: +32 4 2248800; fax: +32 4 2248810.
E-mail address: danielle.hock@chc.be (D. Hock).
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y-nc-nd/4.0/).emain questionable [6–8]. Meanwhile, the current diagnosis
uidelines for individuals with average-risk for CRC only apply
f there is no gastrointestinal symptom or complain [2], raising
otentially important concerns. Indeed, as long as all symptoms
re considered equivalent in terms of diagnostic yield, individ-
als with nonspecific gastrointestinal symptoms are evaluated,
hen needed, by OC, causing potential congestion of the facil-
ties by low resection-rate procedures [9–11]. Second, patient
ompliance to current CRC screening guidelines is low. Almost
0% of asymptomatic subjects 50 years of age and older escape
creening programs over a period of 10 years [12], while subjects
ith nonspecific gastrointestinal symptoms agree to undergoolonic explorations, for reassurance in a greater percentage
7].
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Computed tomography (CT) colonography (CTC) has
merged over the past decade as an accurate and less inva-
ive alternative to OC in series of symptomatic patients [13,14].
imilarly good results were obtained in series of asymptomatic
ubjects [15]. To our knowledge, there are little data evaluating
he test-positive rate according to gastrointestinal symptoms at
TC in the literature. This has implications for risk-stratification
nd potentially impacts CRC screening recommendation. We
herefore evaluate in this study, the distribution of clinically sig-
ificant colonic findings and extra-colonic at CTC, according to
ymptoms and age through a review of a 7-year experience in a
ingle non-academic center.
.  Materials  and  methods
.1.  Patients
Our institutional review board approved the study and autho-
ized this retrospective patient data analysis without further
onsent. We searched our hospital records for all subjects
ho completed a CTC procedure between June 2003 and
ugust 2010. This search yielded 9122 subjects (3822 males,
300 females, average age: 60.11 ±  13.75 years, range: 18–96
ears). Indications for CTC included screening and direct
eferral (n  = 8573), secondary referral after incomplete OC
n = 285), and Double Contrast Barium Enema (DCBE) referral
hange (n  = 264). This referral change was justified by the non-
uperiority of DCBE over CTC for colonic lesions in several
tudies [16,17].
Written informed consent was given by all subjects prior to
rocedures. 1761 subjects with a familial or personal history of
olyps or colorectal cancer, genetic conditions, inflammatory
owel disease, who were at increased- or high-risk for colorec-
al cancer [2] were excluded. The remaining 7361 subjects, with
verage-risk [18] for CRC (general population) (3073 males,
288 females, average age: 60.3 ±  13.9 years, range 18–96
ears) were evaluated. Their clinical status with regard to the
resence of the following gastrointestinal symptoms, prior to
TC was retrieved from the referral forms and/or gathered by
atient’s anamnesis and all other available patient data, includ-
ng: (i) abdominal pain, (ii) constipation, (iii) diarrhea, (iv)
rregular bowel movement, (v) bloating, (vi) melena, (vii) rectal
leeding, and (viii) unexplained weight loss. We retrospectively
ssigned the subjects to three main groups, according to the pur-
orted clinical importance of these symptoms regarding the level
f specificity for CRC [5]: group A included the asymptomatic
ubjects; group B, the patients with one or more nonspecific
ymptom(s) (i–vii) in the absence of an established “alarm”
ymptom (vii and viii), who were assigned to group C.
.2.  CTC  technique
All patients underwent the same standardized procedure that
onsisted into three steps including patient preparation, scan-
ing and data interpretation. The preparation involved two steps
ncluding cathartic colonic cleansing and residual fluid tag-
ing. For patients in good general condition, colonic cleansing
≥
[
O
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as achieved by a one-day clear liquid diet, one bottle of
odium phosphate preparation (Fleet-Phospho-soda®, Wolfs,
wijndrecht, Belgium) and 4 tablets of bisacodyl (Dulcolax®,
oehringer Ingelheim, Ingelheim, Germany). For frail patients,
leansing consisted into 2 days of low-residue diet combined
o 8 g of magnesium–sulphate on the examination day’s morn-
ng, in addition to 2 tablets of bisacodyl and 100 ml of contrast
gent (Gastrografin®, Schering AG, Berlin, Germany) twice a
ay. In patients with renal insufficiency, cardiac failure or severe
ypertension, preparation consisted in 3 days of low-residue diet
ith 2l of Moviprep® (Norgine, Heverlee, Belgium) (propylene-
lycol + ascorbic acid) and 4 tablets of bisacodyl the day before
he study. Residual fluid tagging was obtained by ingestion of
00 ml Gastrografin® the evening before the procedure and total
olonic residual fluid volume was reduced by using a supposi-
ory of bisacodyl approximately 2 h before examination, except
or patients who underwent CTC after incomplete OC. These
atients drank 100 ml of Gastrografin and inserted a suppository
f bisacodyl 1 h before the procedure. Before data acquisition, an
v injection of 20 mg/1 ml of Buscopan® (butylhyoscinbromid
 Boehringer Ingelheim, Bruxelles, Belgium) was performed
nd a rectal cannula was inserted for colonic distension with
n automatic carbon dioxide insufflator VMX-1010A (Vimap
echnologiesTM, Girona, Spain).
A 32-row (GE Lightspeed VCTTM, GE Healthcare, Milwau-
ee, WI) until 09/2010, then a 64-row (GE Discovery CT750
DTM, GE Healthcare, Milwaukee, WI) multislice scanners
ere used for image acquisitions. Parameters consisted into
.2 mm-thick slices with a 0.625 mm reconstruction interval,
sing a 50 mA s low-dose protocols with variable kV, adjusted
o body-density for dose reduction, supplemented since 2010 by
n adaptive statistical iterative reconstruction algorithm (ASIR)
GE Healthcare, Milwaukee, WI). Two acquisitions were per-
ormed: the first in supine position and the second, either in
rone position, or right decubitus for unfit and obese patients.
mmediate review of the images was performed by a radiolo-
ist in all cases. In 897 patients (10%), a third acquisition was
rdered because of a segmental collapse preventing confident
nalysis.
Reading was performed offline on a workstation (Advan-
age Windows, GE Healthcare, Milwaukee, WI) with a software
Colon VCAR) allowing filet-view, supplemented by “com-
uter aided diagnosis” (CAD) assistance from January 2009,
nd electronic cleansing from June 2010. Reconstruction algo-
ithms, image display preferences and reading principles used
or interpretation are described elsewhere [19]. We used C-RAD
eporting classification for all findings [20]. Each finding was
ssigned to both a colonic segment and a distance to the anal
argin.
.3.  Data  analysis
Clinically significant colonic findings were defined as either
6 mm polyps, masses or others requiring work-up or treatment
20]. Clinical files, and reports were searched for repeat CTC,
C and surgical procedures after the initial CTC, when applica-
le. A reviewer was requested to match CTC and the reference
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tandard findings, using available location by segment, and/or
istance from the anal margin. We did not attempt to match using
he size criteria because of known size discrepancies between
C and CTC polyp measurement [21]. Using an “intention
o treat” algorithm, per-patient CTC diagnostic values for the
iagnosis of clinically significant colonic findings were calcu-
ated. Patients with at least one matched finding were considered
rue-positive while patients with CTC findings unmatching the
eference standard were considered as false-positive. Those with
o finding at CTC and at least one positive finding on the refer-
nce standards were considered false-negative.
For patients with several colonic findings, two clinicians
aving access to all available data were requested to deter-
ine in consensus, the most significant with regard to CRC.
or example, an individual with both a >6 mm colonic polyp
nd a non-neoplastic colonic mass accounted, for only the first.
n addition, they were requested to establish a potential cor-
espondence between the clinical symptoms and CTC colonic
nd significant extra-colonic findings (i.e.: E4 grade of the CTC
eporting and Data System, unrelated to a colonic disease)..4.  Statistical  analysis
Percentages are given with their 95% Confidence Inter-
als (CI). Continuous variables are compared using analysis of
i
t
o
o
Include
N=736
N = 645 8 (87.7%)
VC  -
Comparison  to 
OC/surgery/repea t VC
N=1198 (18.5%)
Tru e negati ve : 
1193 (99.6%)
False negative : 
5 (0.4%)
Unverified
N= 5260 ( 81.5%)
Fig. 1. Patient flowchart and diagnostic values of CTC. Between theadiology Open 2 (2015) 32–38
ariance, and two-tailed t-tests are used for direct comparison
etween two groups. Pearson chi-square tests are used to com-
are proportions and percentages. We used a regression analysis
o evaluate the impact of the group of symptoms, age and gender
n the test-positive rate. A p-value of less than 0.05 denotes a
tatistical significance.
.  Results
Fig. 1 summarizes the patient flowchart in this study. 903 out
f the 7361 (12%, 95%CI 11–13%) subjects had at least one
linically significant colonic finding at CTC. Histopathological
iagnoses and/or etiology for the confirmed findings are given in
able 1, showing that the abnormalities were most commonly of
ucosal origin. Comparison of CTC to OC and/or surgery was
ossible for 692/903 (77%; 95%CI 0.074–0.79) of these sub-
ects. CTC findings were confirmed in 637, while 55 patients
ere false-positive. In addition, repeat CTC, OC and/or surgery
as performed within a range of 6–60 months in 1198 sub-
ects with negative CTC findings for the following reasons: 656
atients underwent OC including programmed screening tests
n 168, exacerbation of a “non-alarm” gastrointestinal symp-
om or occurrence of a new symptom in 443, and occurrence
f an “alarm” symptom in 48. 527 patients underwent a sec-
nd CTC including programmed screening tests in 287, new or
d
1
N = 903 ( 12.3%)
VC +
Comparison  to 
OC/surgery/re pea t VC
N= 692  (76.6%)
False positi ve : 
55 (7.9%)
Tru e positi ve : 
637 (92.1%)
Missed
N= 211  (23.4%)
 parentheses are the percentages. Abbreviations as in the text.
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Table 1
Histopathology and causes of confirmed CTC findings in 642 patients.
Causes of findings Confirmed
findings (N = 642)
% 95%CI
Tumors and polyps
Adenocarcinoma 97* 15.10 0.12–0.18
Carcinoid tumor 1 0.15 NA
Gastrointestinal stromal
tumor
1 0.15 NA
Peritoneal metastasis 1 0.15 NA
Bladder cancer infiltration 1 0.15 NA
Villous 11 1.71 0.01–0.03
Tubulovillous 69 10.75 0.08–0.13
Tubular 70** 10.90 0.08–0.14
Hyperplasic 35** 5.45 0.04–0.07
Hamartomatous 1 0.15 NA
Fibrolipoma 1 0.15 NA
Lipoma 4 0.62 0.00–0.01
Post-hemorrhoid scar 1 0.15 NA
Others
Diverticulitis 24 3.73 0.02–0.05
Ischemia 7 1.09 0.00–0.02
Endometriosis 7 1.09 0.00–0.02
Non-specific colitis 1 0.15 NA
Post-radiation colitis 1 0.15 NA
Leiomyoma 1 0.15 NA
Unknown (not recovered
for analysis)
308 48.0 0.44–0.52
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** Including 1 virtual colonoscopy false-negative.
xacerbated “non alarm symptoms in 216 and “alarm symp-
oms” in 24. Twelve patients (all in group B) had surgical
esection after acute diverticulitis.
Five patients were false-negative (2 with >6 mm polyps and
 with cancers). All controlled cases, yield a 637/642 (99.2%,
5%CI 0.98–0.99) true-positive fraction and a 55/692 (7.95%,
5%CI 0.05–0.09) false-positive fraction.
The average number of symptoms per patient was 1.54 ±  0.35
3800, 1524, 662, 29 and 3 patients had respectively 1, 2, 3, 4 and
 symptoms). Abdominal pain and constipation were the most
requent, while unexplained weight loss was the least frequent
ymptom. Groups A, B and C included respectively 1343, 5329
nd 689 patients; their demographic characteristics are given in
able 2. The average age in group C (64.37 ±  14.61 years) was
ignificantly higher than in both groups A (60.96 ±  11.22 years)
nd B (59.43 ±  14.31 years) (p  < 0.001). The male/female ratio
as lower in group B (0.63) versus group A (1.03) (p  < 0.001).
he rate of E4 findings in the C-RAD reporting system was sig-
ificantly higher in group C (44/689, 6.4%, 95%CI 0.04–0.08)
ersus groups A (26/1343, 1.9%, 95%CI 0.01–0.03) and B
64/5329, 1.2%, 95%CI 0.01–0.02) (p  < 0.001). The regression
nalysis showed that the group of symptom (B < C), gender
F < M) and age all significantly impacted the test-positive rate at
TC. When pooling patients by age groups (Table 3), the test-
ositive rate in group C (138/689, 20.0%, 95%CI 0.17–0.23)
as significantly higher than in groups A (79/1343, 5.8%,
5%CI 0.04–0.07) and B (420/5329, 7.8%, 95%CI 0.07–0.08)
p < 0.001), then, across all ages, except for patients younger
e
O
(
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han 50 years of age whose test-positive rate in groups C,
 and B were respectively (6/96, 6.25%, 95%CI 0.01–0.11),
5/173, 2.9%, 95%CI 0.00–0.05) and (47/1241, 3.8%, 95%CI
.02–0.04) (p  = 0.412). Diagnostic values of CTC within the
hree groups are given in Table 4. Both the true-positive frac-
ion that was consistently above 97% in all groups (p  = 0.991)
nd the false-positive fraction did no differ among all groups
p = 0.240).
.  Discussion
In a recent meta-analysis evaluating the value of various
ymptoms for CRC in primary care, Jellema et al. found large
eterogeneities in the sensitivity and specificity of most symp-
oms [6]. Rectal bleeding and unexplained weight loss have
onsistently higher specificity than the others, according to
nother recent meta-analysis [5]. Similarly to studies using
C, the test-positive rate at CTC in our study was higher in
atients with these “alarm” symptoms than in asymptomatic sub-
ects and those with minor gastrointestinal symptoms (p < 0.05).
lthough the average age was also significantly higher in the
alarm” symptoms group (p  < 0.05), age was not a key determi-
ant, since similar differences were observed in all age groups
bove 50 years. In terms of CRC diagnostic recommenda-
ions, a test-positive rate around 20% makes OC the procedure
f choice in patients with “alarm” symptoms, owing to the
igh resection-rate. An exception to this rule, though requir-
ng stronger evidence, may be patients aged less than 50 years.
heir findings prevalence was 6/96 (6.25%; 95%CI 0.01–0.11),
.e.: higher than in age-matched patients, but comparable to the
verall prevalence in the other groups.
Due to the low specificity of the remaining gastrointestinal
ymptoms (alone or in combination), diagnostic recommen-
ations currently fails to avoid OC facilities congestion by
rocedures yielding low rates of resection [9–11,22,23]. Excep-
ion made of melena and hemorrhoids, the “non-alarm”
ymptoms evaluated in this study are commonly described
n patients with irritable bowel syndrome (IBS) which is a
unctional bowel disorder affecting 7–15% of the general pop-
lation in the USA, women being twice more often afflicted
han men [24,25]. Its diagnosis nicely illustrates the dichotomy
etween the daily management of gastrointestinal symptoms
nd evidence-based diagnostic recommendations. Indeed, the
iagnosis of IBS is based exclusively on clinical criteria [26],
ut, up to 75% of clinicians believe that it should be ascer-
ained by exclusion of organic disease [27]. For this purpose,
pproximately half of the patients with known or suspected
BS have undergone at least one diagnostic OC procedure [28].
astly, it has been estimated that 25% of the OC procedures
erformed in the USA are for patients with “non-alarm” gas-
rointestinal symptoms, although the actual risk of CRC in these
atients is not higher than in asymptomatic individuals in sev-
ral studies reporting very close ranges of test-positive rate at
C among IBS (range 1.9–9.3%) and asymptomatic individuals
range 4.5–12.1%) [29,30]. Several reasons could be advocated
or this dichotomy, including physicians and patient’s anxiety,
36 D. Hock et al. / European Journal of Radiology Open 2 (2015) 32–38
Table 2
Patient groups demographics.
Age ± SD (years) Age range (years) Sex ratio C-RAD reporting classification
C0 C1 C2 C3 C4 E4
Group A
(N = 1343)
60.96 ± 11.22 21–91 683M/660F (1.03) 11 1179
(87%)
58
(4%)
55
(4%)
40
(3%)
26
(2%)
Group B
(N = 5329)
59.43 ± 14.31 18–96 1975M/3144F (0.63) 21 4587
(86%)
269
(5%)
287
(5%)
165
(3%)
64
(1%)
Group C
(N = 689)
64.37 ± 14.61 20–95 318M/371F (0.86) 0 594
(86%)
34
(5%)
38
(5%)
23
(3%)
44
(6%)
p-value <0.0001* NA <0.0001** NA 0.906 0.573 0.174 0.916 <0.001*
* Significantly higher (p < 0.05) in group C versus group B and group C versus group A.
** The proportion of males is significantly higher in group A versus group B (p < 0.0001).
NA = not applicable.
C-RAD reporting and data system.
• C0 = inadequate study.
• C1 = normal colon/benign lesion.
• C2 = polyps 6–9 mm in diameter or <3 in number.
• C3 = polyp >10 mm in diameter or >3 polyps with each 6–9 mm.
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p4 = potentially important finding: communicate to referring physician.
ymptoms severity and the lack of evidence that other diagnostic
rocedures may be as accurate or cost-effective than OC.
To our knowledge, our study is the first evaluating colonic
ndings according to gastrointestinal symptoms using CTC.
his was possible as, since 2002, CTC has progressively become
 routine procedure in our institution, acknowledged both by
t
r
t
able 3
TC test-positive rate by age in all groups.
ge (years) Group A Group B 
50 5/173 47/1241 
(2.89%) (3.78%) 
95%CI 95%CI 
0.00–0.05 0.02–0.04
0–59 23/441 91/1362 
(5.21%) (6.68%) 
95%CI 95%CI 
0.03–0.07 0.05–0.08 
0–69 30/420 107/1251 
(7.14%) (8.55%) 
95%CI 95%CI 
0.04–0.09 0.07–0.10 
0–79 14/244 134/1077 
(5.73%) (12.44%) 
95%CI 95%CI 
0.02–0.08 0.10–0.14 
80 7/65 41/398 
(10.77%) (10.30%) 
95%CI 95%CI 
0.03–0.18 0.07–0.13 
otal 79/1343 420/5329 
(5.88%) (7.88%) 
95%CI 95%CI 
0.04–0.07 0.07–0.08 
-value 0.176 <0.0001 
* Significant difference between group C versus groups A and B.
** Significant difference between group C versus groups B.ur gastroenterologists, general practitioners and patients. The
anges of test-positive rate in asymptomatic individuals and
hose with “non-alarm” symptoms were low and comparable
o those reported using OC. In both groups, the test-positive
ate increased roughly linearly with aging (p < 0.05). Given
heir relatively low test-positive rate, patients with “non-alarm”
Group C Total p-value*
6/96 58/1510 0.412
(6.25%) (3.84%)
95%CI 95%CI
0.01–0.11 0.02–0.0.5
22/159 136/1962 (6.93%) 0.003*
(13.83%) 95%CI
95%CI 0.05–0.08
0.08–0.19
42/151 179/1822 (9.82%) <0.0001*
(27.81%) 95%CI
95%CI 0.08–0.11
0.21–0.35
42/180 190/1501 (12.65%) <0.0001*
(23.33%) 95%CI
95%CI 0.10–0.14
0.17–0.29
26/103 74/566 (13.07%) 0.003**
(25.24%) 95%CI
95%CI 0.10–0.16
0.17–0.33
138/689 637/7361 <0.0001*
(20.02%) (8.65%)
95%CI 95%CI
0.17–0.23 0.08–0.09
=0.002 <0.0001 NA
D. Hock et al. / European Journal of R
Table 4
Diagnostic values of CTC versus OC and/or surgery in groups A, B and C.
Abbreviations as in the text.
True-positive fraction False-positive fraction
Group A 79/79 (100%)
(95%CI = NA)
10/89 (11%)
(95%CI 0.04–0.17)
Group B 420/422 (99.5%)
(95%CI 0.98–1.00)
38/458 (8%)
(95%CI 0.05–0.11)
Group C 138/141 (97.9%)
(95%CI 0.95–1.00)
7/145 (5%)
(95%CI 0.01–0.08)
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[6] Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg-value 0.991 0.240
ymptoms may indeed benefit from accurate noninvasive
iagnostic procedures. In our series of 5329 patients with “non-
larm” symptoms, 4088 were older than 50 years of age: it
ay thus be emphasized that these symptoms were an incen-
ive to comply with screening guidelines and should therefore
e carefully sought. Although patients under 50 years of age and
uspected of IBS should not undergo any colonic exploration,
any of them unfortunately do in most institutions, including
urs. In our series, this malpractice applies to 1241 patients (23%
eferred by gastroenterologists) for whom CTC has a low test-
ositive rate in good correlation with other series, but represent
he most comprehensive and the less harmful option as compared
o OC, the standard of reference.
In this setting, our study confirmed that CTC has a high true-
ositive fraction and a low false-positive fraction for polyps and
RC in all groups [15,31] clearly advocating for its recommen-
ation in patients with “non-alarm” gastrointestinal symptoms.
Considering the recommendations guidelines for CRC, the
ain disadvantage of CTC, namely the inability to perform
olypectomy, may raise cost-effectiveness issues. In our study, at
east 420 additional OC were performed in the group of patients
ith “non-alarm” symptoms, while approximately 5000 poten-
ial diagnostic OC procedures were replaced by less expensive
TC procedures, putting obviously the cost-effectiveness bal-
nce in favor of a primary diagnostic procedure by CTC in our
nstitution. In addition, offering a same-day OC after positive
TC scenario currently prevent the need for a second bowel
reparation in most institutions including ours [32]. The abil-
ty to detect clinically significant extra-colonic abnormalities
E4) may also impact CTC cost-effectiveness. A total number
f 134 individuals had E4 findings, which represent an asset
or CTC. Interestingly, the rate of E4 findings distribution per
roup was quite similar to the test-positive rate distribution,
revailing thus in older patients. This indicates that E4 find-
ngs rate are not either increased by nonspecific gastrointestinal
ymptoms. Lastly, the concern of exposure to ionizing radiation
uring CTC, has dropped significantly with the latest gener-
tion of scanners [33]. In our institution, the combined dose
or supine and prone acquisitions of an average-sized subject
s approximately 3 mSv (i.e.: levels comparable to the annual
nvironmental scatter doses).Some limitations may be applied to this study and its conclu-
ions, the first of which is its retrospective nature that resulted
nto several patients lost to follow-up and clinical data missing.adiology Open 2 (2015) 32–38 37
istopathological data were also missing in several patient from
is-retrieved polypectomies that are, however, not uncommon
33]. Reported symptoms were not based on a checklist of all
astrointestinal symptoms. The same design forced us to pool
ymptoms in two groups, resulting into potential masking of the
ffect of one or several underrepresented individual symptom(s)
n the CTC test-positive rate. Moreover, age of symptoms onset,
heir intensity and duration lacked, preventing a better detailed
elationship between symptoms and test-positive rate. Reported
iagnostic values of CTC, though comparable with previously
eported studies, are subject to verification bias, since OC was
ostly performed when CTC was positive. In addition, most
f the unverified CTC positive cases were small polyps, which
robably decreased artificially the false-positive rate. Lastly,
atients with at least one gastrointestinal symptom largely out-
umbered asymptomatic subjects in our study, with 6929 out of
he 7361 average-risk subjects for CRC having at least one symp-
om. This selection bias was caused by a progressive referral
eplacement of DCBE by CTC during the study period.
.  Conclusion
In conclusion, asymptomatic subjects, patients with “non-
larm” gastrointestinal symptoms and even young patients
ith “alarm” symptoms for CRC have nearly similarly low
est-positive rates at CTC. Overall, the rate of colonic and
xtra-colonic findings increased with age, male gender and the
resence of “alarm” symptoms for CRC. The high diagnostic
alue of CTC in all patient groups makes it the examination of
hoice in low-yield patients; who include asymptomatic subjects
nd those with “non-alarm” gastrointestinal symptoms.
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